RxSight (RXST) Q2 Loss Beats Estimates

RxSight (NASDAQ:RXST), a U.S.-based ophthalmic medical device company, reported its second quarter 2025 financial results on August 7, 2025. The most notable developments in the release were a lower-than-expected GAAP revenue outcome alongside a marked improvement in profitability metrics, with GAAP gross margin rising from 69.5% in Q2 2024 to 74.9% in Q2 2025. GAAP revenue was $33.6 million, missing analyst estimates of $34.79 million and down from $34.9 million in Q2 2024. Despite this, Non-GAAP adjusted net loss per share was $(0.08), materially outperforming the $(0.25) consensus non-GAAP EPS estimate. This quarter saw a 13% increase in Light Adjustable Lens procedures compared to Q2 2024, improved GAAP gross margin to 74.9% from 69.5% in Q2 2024, but also wider operating losses driven by rising expenses. Overall, the period underscores the progress in high-margin consumable sales, as well as the challenges in capital system placements and expense control. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. RxSight is a medical device company specializing in innovative intraocular lens technologies. Its primary offering is the Light Adjustable Lens (LAL), which enables surgeons to customize a patient’s vision after cataract surgery through a series of painless UV light treatments. The associated Light Delivery Device (LDD) provides physicians the tool necessary for lens adjustment, creating a unique value proposition in the premium cataract lens market. This differentiated approach allows patients to achieve superior visual outcomes, as shown by Clinical trial data from the FDA trial indicate that 70% of LAL patients achieved 20/20 or better uncorrected visual acuity without glasses, compared to about 40% of patients with standard premium lenses in similar studies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool